Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda by Ssebambulidde, Kenneth et al.
Oxford Medical Case Reports, 2019;2, 79–82
doi: 10.1093/omcr/omy132
Case Report
C A S E R E PORT
Symptomatic cerebrospinal fluid HIV-1 escape in two
patients on second-line antiretroviral therapy in
Uganda
Kenneth Ssebambulidde1,*, Ivan Segawa2, Eva Laker1,
Mohammed Lamorde1, Barbara Castelnouvo1, Noeline Nakasujja1,2
and Andrea Calcagno3
1Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda, 2College of
Health Sciences, Makerere University, Kampala, Uganda, and 3Unit of Infectious Diseases, Department of
Medical Sciences, University of Torino, Torino, Italy
*Correspondence address. Department of Research, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Tel: +256-41-453-0020; E-mail: kssebambulidde@idi.co.ug
Abstract
Two HIV-infected individuals on second-line atazanavir-based antiretroviral therapy presented with neuropsychiatric
symptoms. Cerebrospinal fluid HIV RNA was higher than plasma HIV RNA and antiretroviral regimens’ optimization led to
prompt resolution of symptoms in one. Patients on second-line atazanavir-based antiretroviral therapy with documented
previous treatment failure may be at risk of symptomatic cerebrospinal fluid escape.
INTRODUCTION
Cerebrospinal fluid (CSF) HIV escape in individuals on antiretro-
viral therapy (ART) is defined as a detectable CSF HIV RNA with a
concurrent undetectable plasma level, or CSF HIV RNA higher
(any level, 0.5 or 1 log) than plasma HIV RNA. It has been reported
in 0.7–27.4% asymptomatic HIV-infected individuals on ART [1].
Symptomatic CSF escape has been described in more than
100 individuals but never in limited resource countries.
Patients usually present with subacute neurological symptoms,
CSF HIV RNA higher than plasma levels and with resistance
associated mutations (RAMs). Risk factors include low nadir
CD4 cell count, incomplete plasma viral suppression and poor
adherence [2, 3]. Two recent case series from India and one
large cohort suggest that it may be more frequent in patients
on protease inhibitors (PIs), but this may be biased by the pres-
ence of RAMs [4–6]. Treatment is usually with optimization of
ART through choosing drugs according to genotype resistance
test results and their central nervous system penetration/
effectiveness score (CPE).
Here; we describe two Ugandan patients on PIs based
second line ART for at least 7 years at the time of presentation
with neuropsychiatric symptoms associated with uncontrolled
central nervous system HIV compartmental replication.
CASE 1
A 62-year-old male, HIV-infected on second-line ART for 7
years with a nadir CD4 T-cell count of 158 cells/μL. He was
referred to the Infectious Diseases Institute, Kampala from a
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mental health unit for further assessment of his neurocognitive
decline. He had been well till 8 months prior to his referral
when he started having; memory impairment, visual hallucina-
tions, sleepiness, unstable gait and being scared of falling. He
had no history of headache or head trauma. He was taking
Donepezil 2.5mg daily for early onset dementia for 8 months
by the time of his referral. He had no history of substance
abuse and no family history of mental illness. His cognitive
decline had impaired his daily activities. He stopped working
due to memory impairment and was unable to move unsup-
ported. He needed help for his daily activities including; wash-
ing himself, dressing up and ambulation. He could not
recognize anyone in his family including his wife and children.
He initiated ART 18 years prior to his referral. The antiretro-
viral regimen he had taken for the first 4 years was unknown
after which he was switched to tenofovir, lamivudine and efavir-
enz which he took with inconsistent adherence for 7 years
before being switched to second line therapy due to viral failure
(plasma HIV RNA; 4014 copies/mL). His second line regimen con-
sisted of zidovudine, lamivudine and ritonavir-boosted atazana-
vir. He achieved plasma virological suppression (HIV RNA < 75
copies/mL) in the first 5 years of this second line regimen. He
had no prior history of an AIDS-defining opportunistic illness.
Clinically, he was slightly overweight (BMI 26 kg/m2), afeb-
rile, the blood pressure was 158/96mmHg and a pulse of 96
beats per minute; his speech was characterized by confabulat-
ing, challenges in maintaining attention, had intentional tre-
mors and a shuffling gait.
A lumbar puncture was performed as part of his investiga-
tions for his neurocognitive decline. CSF had normal opening
pressure at 11cmH2O, with a normal white cell count (<5 cells/
μL), normal total protein (12mg/dL), an elevated glucose level of
11.7mmol/L as compared to plasma 7.6mmol/L and the veneral
disease research laboratory (VDRL) test was negative. The CSF
HIV RNA was 4 895 copies/mL (3.69 log units) and plasma HIV
RNA was 277 copies/mL. Other laboratory findings included;
CD4 T-cell count of 503 cells/μL normal renal and liver function
tests, hyponatremia (127mmol/L), HbA1C 6.6%, and elevated
fasting triglycerides (2.2mmol/L).
He had a normal brain CT scan. However, magnetic reson-
ance imaging (MRI) of his brain showed neuroparenchymal
atrophy and hyperintensities involving bilateral periventricular
white matter; features suggestive of HIV encephalitis (Fig. 1).
Plasma drug sensitivity tests done showed several RAMs:
I50L and others (L10V, I13V, K14R, I15V, E35D, M36I, R41K, R57K,
I64V, H69K, T74A, L89M) in the protease gene, several muta-
tions in the reverse transcriptase gene both for NRTIs (T215F,
K219E, D67H, K70R, L74I, M184V) and NNRTIs (K103N, V179T,
P225H). CSF HIV drug sensitivity testing was not available.
Basing on the resistance profile results, his ART regimen was
changed to dolutegravir, lamivudine and ritonavir boosted lopina-
vir. This increased his central nervous penetration effectiveness
score from 5 to 8. He is registering on-going improvement in his
subsequent follow-up visits. Gait normalizing, memory impairment
resolving within 2 months of follow up. His sodium improved to
137mmol/L. His plasma HIV RNA was suppressed within a month
of ART change. He was now able to move without support and rec-
ognize family members. He returned to work with no one escorting
him in his third month of ART change. Donepezil was tapered off.
CASE 2
A 58-year-old female diagnosed with HIV and cryptococcal
meningitis 12 years prior to her admission to Mulago National
Referral Hospital. Her initial ART regimen included zidovudine,
lamivudine and nevirapine and had a nadir CD4 T-cell count of
263 cell/μL (current). Nine years following ART initiation, she
was diagnosed with sputum positive pulmonary tuberculosis
for which she received anti-tuberculous therapy for 6 months
and was declared cured. Following her pulmonary tuberculosis
treatment, she was found to have virologic failure (plasma HIV
RNA of 170 694 copies/mL) and was switched to tenofovir,
lamivudine and ritonavir boosted atazanavir. Plasma HIV RNA
was <75 copies/mL a year after her switch, and low viremia 2
years after the switch (HIV RNA; 251 copies/mL) and an ele-
vated fasting blood sugar (8.9mmol/L) was found for which
metformin 500mg daily was added to her treatment.
She was admitted to Mulago National Referral Hospital with
urinary incontinence and irritability but no constitutional
symptoms. Of note, she had progressively had lower limb
weakness over a year resulting in inability to move, and had
been bedridden for 3 months. This was associated with short
term memory loss and abnormal picking on herself articles
that were never seen by other individuals and unusual postur-
ing of her neck (mannerisms). She was always in and out of
confusion for over 2 months.
Clinically, she had an axillary temperature of 36.2°C, fast
regular normal volume pulse of 111 bpm, normal blood pres-
sure 104/88mmHg, saturating at 98% on room air, respiratory
rate of 20 bpm. She had mannerisms and poor eye contact. She
was paraplegic with a staggering gait on moving with support.
A lumbar puncture was performed; CSF was under normal
opening pressure at 14 cmH2O with normal CSF protein 48mg/
dL, elevated white cell count 220 cells/μL 100% lymphocytes.
Negative gram stain, cryptococcal antigen, MTB/Rif GeneXpert
and ultra Xpert and no fungal or bacterial or mycobacterial
growth on culture. Her CSF HIV RNA was 31 896 copies/mL
(4.50 log units) with a plasma HIV RNA of 1804 copies/mL
(3.26 log units). She was diagnosed with symptomatic CSF HIV
escape. We await her plasma HIV drug sensitivity test results
to optimize her ART.
DISCUSSION
We here report the first two cases of symptomatic CSF HIV
escape from Uganda; it should be noted that CSF HIV RNA is
not usually measured in the routine work up for unexplained
neurological symptoms in HIV-infected individuals. In many
resource limited countries, the application of World Health
Organization guidelines may result into the ‘perfect’ scenario
for the compartmental replication of HIV. The use of low gen-
etic barrier first-line therapy, delayed antiretroviral switch due
to infrequent viral load monitoring and at a higher cut off (1000
copies/mL) as well as the recycling of some nucleotide reverse
transcriptase inhibitors (NRTIs) for second line treatment might
favour selection of RAMs.
Of the PIs routinely available in Uganda, atazanavir has the
least CPE score of 2 compared to lopinavir and darunavir each
with a CPE score of 3 [7]. Atazanavir has been associated with
more reports of CSF HIV escape than lopinavir [8]. In Uganda,
however, atazanavir is preferred to lopinavir for second line
antiretroviral regimens due to its affordability, gastrointestinal
tolerability and reduced pill burden [9]. The presence of several
RAMs may therefore expose patients to atazanavir monother-
apy. Several studies reported the possibility of symptomatic
CSF escape in patients with low nadir CD4 T-cell count on PI
monotherapy. Low CD4 nadir seems the strongest risk factor
for symptomatic CSF escape: in one the two Indian studies its
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incidence was 9.5 per 10 000 person-months in patients with
nadir CD4 cell count below 200/μL versus 0.49 per 10 000
person-months in those ones with higher levels [4]. However,
CSF escape is rare in individuals on robust highly active ART
with atazanavir as one of the drugs unless they also have
RAMs.
The two patients described had their HIV diagnoses 18 and
12 years ago with current CD4 counts of 504 and 263, respect-
ively. They were both on ritonavir boosted atazanavir based
ART. Their characteristics are similar to other patients previ-
ously described with CSF HIV escape [5, 10]. Cases 1 and 2 had a
CSF/plasma HIV RNA log difference of 1.25 log units and 1.24 log
units respectively characteristic of CSF HIV escape.
Symptomatic neurocognitive impairment has been reported
in 35.1% of individuals with CSF HIV escape [11]. The more
commonly described symptoms in individuals with CSF HIV
escape include; memory impairment, gait disturbances, sleep
disorders and inability to concentrate. These symptoms were
noted in both patients we have described. Case 2 had worse
symptoms compared to case 1. This could be as a result of
overwhelming inflammation from the higher CSF HIV RNA
level noted compared to that found in case 1.
In a setting where adults with HIV infection, even with ART,
are more likely to have cognitive dysfunction than those with-
out HIV infection [12], it is only prudent that CSF HIV RNA
evaluation is added to their routine diagnostic evaluation. This
Figure 1: Magnetic resonance image of the brain: symmetric T2/FLAIR hyperintensities involving bilateral periventricular white matter, fronto-temporo-parietal sub-
cortical white matter and centrum semiovale. Neuroparenchymal atrophy. Dilated and prominent cerebral ventricles, sulci and cisterns. Features usually representa-
tive of HIV associated encephalitis.
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will facilitate optimization of their ART to better central ner-
vous system penetrating/effective regimens.
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